+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Alcoholic Hepatitis Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook

  • PDF Icon


  • 72 Pages
  • July 2020
  • Region: Global
  • VPA Research
  • ID: 5130038
2020 Alcoholic Hepatitis PIPELINE HIGHLIGHTS

Alcoholic Hepatitis is one of the widely researched conditions during 2020 with 14 companies actively focusing on realizing pipeline’s potential. Development of Alcoholic Hepatitis medicines is identified as integral to the strategy of the majority of companies operating in the industry.

Global Alcoholic Hepatitis market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Alcoholic Hepatitis.

Good progress is anticipated during 2020 and 2021 with Alcoholic Hepatitis pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Alcoholic Hepatitis pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.


The “Alcoholic Hepatitis pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.

This Alcoholic Hepatitis pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Alcoholic Hepatitis presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Alcoholic Hepatitis pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.

Alcoholic Hepatitis DRUG PROFILES

Alcoholic Hepatitis development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided:
  • Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
  • Phase of development
  • Mechanism of Action
  • Route of Administration
  • Companies involved including originator, licensing companies, developer, investors, and others
  • New molecular entity details
  • Orphan drug designation and other special status provided by regulators

Alcoholic Hepatitis COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Alcoholic Hepatitis drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Alcoholic Hepatitis. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 14 Alcoholic Hepatitis companies including company overview, key snapshot, contact information, and their strategies on accelerating Alcoholic Hepatitis pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Afimmune Biopharma Ltd, DURECT Corporation, Generon Corporation (Shanghai) Ltd., Gilead Sciences Inc, Intercept Pharmaceuticals Inc, Novartis AG, Pattern Therapeutics, PharmaKing Co Ltd, Rejuvenation Technologies Inc, Vectus Biosystems Ltd, Verlyx Pharma Inc, Virpharm Pharmaceutical Co, Vital Therapies, EndoProtech Inc

Reasons to Buy
  • The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
  • This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
  • Buyers can identify most promising drug candidates for treatment of Alcoholic Hepatitis
  • It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
  • Users can estimate possible delays in the delivery of pipeline or launch of new products
  • Stay ahead of competition through understanding their pipeline progression, strategies and outlook
  • The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
  • Optimize your licensing and technology transfer strategies through identification of prospect partners

Table of Contents

1. Introduction to Alcoholic Hepatitis
1.1 Alcoholic Hepatitis- Disease overview
1.2 Alcoholic Hepatitis- Market Size
1.3 Alcoholic Hepatitis- Companies Involved
2. Alcoholic Hepatitis Pipeline Snapshot- 2020
2.1 Alcoholic Hepatitis Pipeline by Phase
2.2 Alcoholic Hepatitis Pipeline by Mechanism of Action
2.3 Alcoholic Hepatitis Pipeline by Route of Administration
2.4 Alcoholic Hepatitis Pipeline- New Molecular Entities
2.5 Alcoholic Hepatitis Pipeline- Orphan Drug Designation/ Special Designation
3. Alcoholic Hepatitis Drug Profiles
3.1 Current Status
3.2 Alcoholic Hepatitis Drug Snapshot
3.3 Alcoholic Hepatitis Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4. Company wise Pipeline and Trials
4.1 Afimmune Biopharma Ltd Alcoholic Hepatitis Pipeline Insights and Clinical Trials
4.2 DURECT Corporation Alcoholic Hepatitis Pipeline Insights and Clinical Trials
4.3 Generon Corporation (Shanghai) Ltd. Alcoholic Hepatitis Pipeline Insights and Clinical Trials
4.4 Gilead Sciences Inc Alcoholic Hepatitis Pipeline Insights and Clinical Trials
4.5 Intercept Pharmaceuticals Inc Alcoholic Hepatitis Pipeline Insights and Clinical Trials
4.6 Novartis AG Alcoholic Hepatitis Pipeline Insights and Clinical Trials
4.7 Pattern Therapeutics Alcoholic Hepatitis Pipeline Insights and Clinical Trials
4.8 PharmaKing Co Ltd Alcoholic Hepatitis Pipeline Insights and Clinical Trials
4.9 Rejuvenation Technologies Inc Alcoholic Hepatitis Pipeline Insights and Clinical Trials
4.10 Vectus Biosystems Ltd Alcoholic Hepatitis Pipeline Insights and Clinical Trials
4.11 Verlyx Pharma Inc Alcoholic Hepatitis Pipeline Insights and Clinical Trials
4.12 Virpharm Pharmaceutical Co Alcoholic Hepatitis Pipeline Insights and Clinical Trials
4.13 Vital Therapies Alcoholic Hepatitis Pipeline Insights and Clinical Trials
4.14 EndoProtech Inc Alcoholic Hepatitis Pipeline Insights and Clinical Trials
5. Alcoholic Hepatitis Market News and Updates
6. Appendix
6.1 Sources and Methodology
6.2 Contact Information

Companies Mentioned

  • Afimmune Biopharma Ltd
  • DURECT Corporation
  • Generon Corporation (Shanghai) Ltd.
  • Gilead Sciences Inc
  • Intercept Pharmaceuticals Inc
  • Novartis AG
  • Pattern Therapeutics
  • PharmaKing Co Ltd
  • Rejuvenation Technologies Inc
  • Vectus Biosystems Ltd
  • Verlyx Pharma Inc
  • Virpharm Pharmaceutical Co
  • Vital Therapies
  • EndoProtech Inc